Sanofi MS Drug Tolebrutinib Misses Goal in Relapsing Disease Trials

By Ludwig Burger(Reuters) - Sanofi's most advanced multiple sclerosis (MS) drug candidate has missed the main goal of two late-stage trials to...

By Ludwig Burger(Reuters) - Sanofi's most advanced multiple sclerosis (MS) drug candidate has missed the main goal of two late-stage trials to...